EP4687905A1 — Compositions for inducing ras gtp hydrolysis and uses thereof
Assigned to Revolution Medicines Inc · Expires 2026-02-11 · 0y expired
What this patent protects
The present disclosure relates to therapies for treating cancer. In particular, the present disclosure relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a RAS(ON) GTP hydrolysis-promot…
USPTO Abstract
The present disclosure relates to therapies for treating cancer. In particular, the present disclosure relates to methods of treating cancer in a subject in need thereof, comprising administering to the subject a therapeutically effective amount of a RAS(ON) GTP hydrolysis-promoting compound optionally in combination with an additional therapeutic agent (e.g., a RAS(OFF) inhibitor, RTK inhibitor, SHP2 inhibitor, or SOS1 inhibitor), pharmaceutical compositions comprising a therapeutically effective amounts of the inhibitor(s), kits comprising the compositions and methods of use therefor.
Drugs covered by this patent
- Gavreto (PRALSETINIB) · Rigel Pharms
Bibliographic data sourced from FDA Orange Book + USPTO public records. Plain-English summary generated by AI grounded in source text. Patent term extensions (PTR, SPC, pediatric) may shift the effective expiry. Not legal advice.
Track this patent
Get a daily-checked alert when vulnerability score, expiry, classification, or assignee changes. Email, Slack, or Teams delivery. Pro: 50 watches, Free: 3.